Myeloproliferative neoplasms are frequently associated with aberrant constitutive tyrosine kinase (TK) activity resulting from chimaeric fusion genes or point mutations such as BCR-ABL1 or JAK2 V617F. We report here the cloning and functional characterization of two novel fusion genes BCR-RET and FGFR1OP-RET in chronic myelomonocytic leukemia (CMML) cases generated by two balanced translocations t(10;22)(q11;q11) and t(6;10)(q27;q11), respectively. The two RET fusion genes leading to the aberrant activation of RET, are able to transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage. The RET fusion genes seem to constitutively mimic the same signaling pathway as RAS mutations frequently involved in CMML. One patient was treated with Sorafenib, a specific inhibitor of the RET TK function, and demonstrated cytological and clinical remissions.
INTRODUCTION
Hematopoietic myeloid malignant diseases are classified in three broad categories according to the maturation potential of the leukemic cells, from the less mature to the more differentiated: acute myeloid leukemias (AML), myelodysplastic syndromes and myeloproliferative neoplasms (MPNs). Chronic myelomonocytic leukemias (CMML) are characterized by a proliferative disease affecting both myeloid and monocytic lineages and by cytological signs of myelodysplasia. The 2008 World Health Organization (WHO) classification has recognized its particularities by distinguishing CMML from myelodysplastic syndrome and MPNs. 1 CMML are defined by persistent peripheral blood monocytosis (41 G/L), absence of the BCR-ABL1 fusion gene, less than 20% of myeloblasts or monoblasts in the blood or the bone marrow and evidence of dysplasia in myeloid lineages. In the absence of dysplasia, acquired cytogenetic abnormalities or persistent monocytosis without classical causes are alternatives to these criteria. The usual age of presentation of CMML is in the range of 70 years. A closely related form of CMML is found in childhood and named juvenile myelomonocytic leukemia. 1 MPNs are frequently associated with a constitutive tyrosine kinase (TK) activity resulting from chimaeric fusion genes or point mutations. Examples of such activations in MPN are BCR-ABL1 in chronic myeloid leukemia or JAK2 V617F in polycythemia vera and essential thrombocytemia. 2 We report here the cloning and functional characterization of two novel fusion genes BCR-RET and FGFR1OP-RET in CMML cases generated by two balanced translocations t(10;22)(q11;q11) and t(6;10)(q27;q11), respectively.
It is the first report of the involvement of the RET TK in hematological malignancies. RET, initially identified as an oncogene in an NIH-3T3 transformation assay, 3 encodes a 1114 amino-acid protein that belongs to the TK receptor sub-family. It binds glial-derived neurotrophic factor (GDNF) ligands associated with co-receptors (GDNF-family a co-receptors; GFRa). Upon ligand binding, the receptor dimerizes and its intracellular tyrosine residues are phosphorylated leading to kinase activation. 4 The direct implication of RET in cancer was evidenced in papillary thyroid carcinoma, where somatic rearrangements result in the fusion of its TK catalytic domain with a N-terminal dimerization domain encoded by various genes. 5 More recently, fusion involving RET merged to KIF5B have been characterized in 1-2% of colorectal and lung carcinomas. 6, 7 Subsequently, point mutations were discovered in the majority of familial or sporadic cases of multiple endocrine neoplasia syndromes 2A/2B (MEN2A/MEN2B). 8 Either RET fusion proteins or point mutations enhance the RET TK activity. 4 Conversely, inactivating mutations lead to renal agenesis and have been found in familial and sporadic cases of Hirschsprung's disease, a developmental disorder characterized by the absence of enteric ganglia in the intestinal tract. 9 The two RET fusion genes described here leading to the aberrant activation of RET, are able to transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage. We also report that the patient associated with the BCR-RET fusion protein didn't respond to Imatinib but was sensitive to Sorafenib, an inhibitor of TK activity.
MATERIALS AND METHODS

Karyotype and fluorescence in situ hybridization (FISH)
Karyotypes were established from bone marrow aspiration after 24-h cultures. Chromosome abnormalities were identified with RHG banding and GTG banding in case 1 and RHG banding in case 2. RET-specific probes were prepared by labeling RET-specific fosmids from the WIBR-2 human fosmid library. 10 Fosmid G248P84737G5 spanned from the 5 0 /centromeric region to RET intron 11 (GRCh37/hg19 assembly location Chr10: 43 564 608-43 610 954) and was labeled with Spectrum Orange. Fosmid G248P82944G3 spanned from the end of RET intron 1 to 3 0 /telomeric region of RET (GRCh37/hg19 assembly location Chr10: 43 591 944-43 636 084) and was labeled with fluorescein isothiocyanate.
RET fusion gene RT-PCR
The specific RT-PCR of the FGFR1OP-RET fusion transcript in case 1 was performed using FGFR1OP Ex6-F (5 0 -CATTCTCCACCAAAGTCACCA-3 0 ) and RET_R2555 (5 0 -CCTGGCTCCTCTTCACGTAG-3 0 ). The reverse fusion transcript RET-FGFR1OP was looked for using RET_F1925 (5 0 -CAACATTTGCCCTCAG-GACT-3 0 ) and FGFR1OP_R1206 (5 0 -GCAAGGCACCAATAGAGAGC-3 0 ). The specific RT-PCR of the BCR-RET fusion transcript in case 2 was performed using four BCR forward primers . ABL1 was used as ubiquitous control gene and quantified using the EAC Taqman set. 11 RET quantification was performed in 98 AML, 31 CMML, 2 normal peripheral blood and 3 normal bone marrow samples. RET TK domain was resequenced in complementary DNA of samples expressing RET at a RET/ ABL1 ratio higher than 0.1 using HsRET_TKDomain_F2 (5 0 -TTCC CGGTCAGCTACTCCTCT-3 0 ) and HsRET_TKDomain_R2 (5 0 -GCATGTTT CTTCCCCTTGTGA-3 0 ).
Retroviral production
Full-length RET fusion transcripts were amplified using Advantage 2 Polymerase Mix (Clontech, Saint-Germain-en-Laye, France) with BCR_ 742U21_SI (5 0 -AGTACTAGTACTCGGCCGCGCCATGGTGGACCC-3 0 ) and RET_ 3817L30_BI (5 0 -GGATCCGGATCCAAAAACGAGTCTGCCACCTGGGAACTGA-3 0 ) for BCR-RET and FGFR1OP_200U25_SI (5 0 -AGTACTAGTACTCGCGGCTTCGGC GGTTGTCTTGGAG-3 0 ) and RET_3817L30_BI for FGFR1OP-RET and cloned into the pMSCV-IRES-EGFP (MIE) retroviral vector. MIE-BCR-ABL1 P210 was kindly provided by Ali Turhan (Poitiers, France). Retroviruses were prepared using the packaging cell line Phoenix-Eco. Retroviral supernatant was collected and filtered through a 0.45-mm filter.
Lineage-negative cells transduction
Bone marrow cells were harvested from 6-to 12-week-old C57BL/6 mice. Lineage-negative (Lin À ) cells were obtained after separation using the Lineage Cell Depletion Kit (Miltenyi Biotec, Paris, France), according to the manufacturer's instructions. Lin À cells were infected with MIE, MIE-BCR-RET, MIE-FGFR1OP-RET or MIE-BCR-ABL1
P210 as previously described. 12 Serial replating was performed as described by Lavau et al.
13
BaF/3 cell line transformation assay
MIE-BCR-RET, MIE-FGFR1OP-RET and MIE-BCR-ABL1
P210 retroviruses were transduced in the BaF/3 cell line regarding its dependency to IL3 for growth. Three independent infections were performed for each fusion gene. Cells were recovered in IL3-containing medium for 48 h and then plated out in presence or absence of 10 ng/ml of IL3 (Peprotech, Neuilly sur Seine, France). Cells were counted daily for 4 days.
Western blot
Infected BaF/3 cells cultured with IL3 were sorted using the EGFP fluorescence (infected cells cultured in absence of IL3 were already 100% EGFP-positive). Antibodies used recognized ABL1 (Merck-Calbiochem, Darmstadt, Germany, #OP20), AKT (Cell Signaling, Saint Quentin en Yvelines, France, #9272), phospho-AKT (Ser473, Cell Signaling, #9271), bcatenin (Becton-Dickinson, Le Pont de Claix, France, #610154), phospho-bcatenin (Ser33/Ser37/Thr41, Cell Signaling, #9561), ERK1/2 (Cell Signaling, #9102), diphosphorylated ERK1/2 (Sigma, M8159), STAT3 (Cell Signaling, #9139), phospho-STAT3 (Tyr705, Cell Signaling, #9131), STAT5 (Cell Signaling, #9363), phospho-STAT5 (Tyr694, Cell Signaling, #9351) and RET (Cell Signaling, #3223).
Morphological and confocal immunofluorescence microscopy
Infected BaF/3 cells were centrifuged onto glass coverslips for 3 min at 300 r.p.m. in a cytospin centrifuge. Rabbit anti-RET (1/100, Cell Signaling, #3223) or normal rabbit control IgG1 (1/100, eBiosciences, Paris, France) antibodies were added for 3 h at room temperature. Fluorescence images were taken using an upright laser scanner confocal microscope (Carl Zeiss LSM710, Le Pecq, France, Â 63 oil immersion objective).
RESULTS
Recurrent 10q11 chromosomal band translocations occur in CMML
The rearrangement of the 10q11 chromosomal band was identified in two independent CMML cases. Case 1 is a 12-week infant who presented initially with melena and hepato-splenomegaly. Blood test revealed a fluctuant hyperleucocytosis (49-88 G/L) with monocytosis (20-24%), myelemia, eosinophilia, thrombocytopenia (34 G/L) and anemia (Hb 8.8 g/dl). The bone marrow aspiration identified 12% of monocytes and less than 2% monoblastic cells. A diagnosis of juvenile myelomonocytic leukemia was established. The karyotype identified a t(6;10)(q27;q11) balanced translocation (Supplementary Figure 1A) . At 2 months of follow-up, a femoral granulocytic sarcoma occurred with a massive osteolytic infiltration by a monocytic population with the same translocation t(6;10)(q27;q11) associated to additional abnormalities, specially a triplication of the derivative chromosome 6: 53,XY, þ 2,6, t(6;10)(q27;q11), þ der(6)t(6;10)x2,
Case 2 is a 69-year-old male, whose disease was revealed by a splenomegaly of 13 cm associated with a hyperleucocytosis (63.7 G/L) along with myelemia (35%), monocytosis (3.2 G/L) and thrombocytosis (527 G/L). The bone marrow aspiration revealed a hyperplasia with 1% of myeloblast and 4% of promyelocytic cells. A diagnosis of CMML1 was established. The karyotype identified a t(10;22)(q11;q11) balanced translocation with a loss of chromosome Y (Supplementary Figure 1B) .
The RET TK gene is the target of 10q11 translocations The 6q27 chromosomal band, involved in case 1, is a recurrent breakpoint region in MPN involving FGFR1OP already reported in fusion with the FGFR1 gene.
14 FISH analysis confirmed its involvement in the t(6;10)(q27;q11) translocation (data not shown). In the 10q11 chromosomal band, RET gene was thought to be a good candidate, as being the unique gene encoding a TK located in this region. The breakpoint in the RET gene was confirmed by FISH analysis (Supplementary Figure 1C) . The FGFR1OP-RET fusion transcript was amplified by RT-PCR (Supplementary Figure 1D) . This product merged FGFR1OP exon 12 with RET exon 12 (Supplementary Figure 1G) . The reverse RET-FGFR1OP fusion transcript was not detected in case 1 (data not shown).
The BCR gene is located in the 22q11 chromosomal band and is frequently involved in chronic myeloproliferative disease. FISH analysis confirmed its involvement in the t(10;22)(q11;q11) translocation (data not shown). The breakpoint in RET gene was also confirmed by FISH analysis (Supplementary Figure 1E) . The BCR-RET fusion transcript was amplified by RT-PCR (Supplementary Figure 1F) and sequenced. This product merges the BCR exon 4 with the same RET exon 12 as in case 1 (Supplementary Figure 1H) .
RET gene is expressed in myeloid neoplasias TKs are often activated in hematological malignancies by forced dimerization due to the juxtaposition of kinase domain and dimerization motifs brought by the fusion partner (such as BCR or FGFR1OP). Furthermore, these fusions often result in an aberrant expression of the kinase domain, as the regulatory elements are brought by the fusion's 5 0 partner gene. We then checked the expression of RET in normal peripheral blood and bone marrow, in 98 AML and 31 CMML cases by quantitative PCR including case 2. Case 2 expressed RET at a high level (RET/ABL1 ratio 0.55) compared with the normal counterparts (RET/ABL1 ratio: 0.004 for blood and 0.006 for bone marrow). AML and CMML cases expressed RET at a lower level than case 2 (RET/ABL1 ratio range: 0.33-0.0001, Supplementary Figure 2) . We sequenced the TK catalytic domain of 6 AML and 7 CMML patients expressing RET at a RET/ABL1 ratio higher than 0.1, but detected no mutation of the TK domain (data not shown).
Patient carrying the BCR-RET fusion gene is insensitive to Imatinib but sensitive to Sorafenib After the diagnosis of case 2, the white blood cell count increased rapidly ( Figure 1 ). The patient was initially treated using Imatinib 400 mg per day (Gleevec, Novartis, Rueil-Malmaison, France) during 2 months. This treatment was discontinued owing to the continuous increase of white blood cells (Figure 1) . After identification of the fusion involving the RET TK gene, the patient was treated with Sorafenib (Nexavar, Bayer, Lyon, France). This drug was selected according to its in-vitro inhibition of TK activity against RET and its commercial availability (Supplementary Table 1) . 15, 16 Sorafenib was initially provided at a dose of 800 mg/day, displaying a major clinical (reduction of the spleen enlargement) and hematological (normalization of the white blood count) remission (Figure 1) . However, no cytogenetic and molecular remissions were achieved (Figure 1 ). The dose of Sorafenib was progressively reduced due to intolerance (hair loss; weight decrease) to 400 mg/day and later to 200 mg/day. The patient is still in complete clinical remission after 27 months of treatment.
Case 1 was rapidly allografted in complete remission. The blood count normalized. He is currently in complete remission with chronic GVHD at 3 years of follow-up.
RET fusion genes confer independence of IL3 to the BaF/3 cell line BCR-RET and FGFR1OP-RET complementary DNA were expressed in BaF/3 cell line using retroviral vectors and compared with the effect of BCR-ABL1 P210 in a transformation assay regarding its dependency of IL3 for growth. In presence of IL3, no difference of growth was observed between mutants compared with the nontransduced cells or infected cells by the MIE retrovirus ( Figure 2 ). In contrast, withdrawal of IL3 was followed by continuous growth of BaF/3 infected by MIE-BCR-RET and MIE-FGFR1OP-RET retroviruses in a similar way to MIE-BCR-ABL1
P210 . As controls, the uninfected BaF/3 cells or infected with the MIE vector died rapidly in absence of IL3 (Figure 2 ).
RET fusion proteins signaling is different from BCR-ABL1
BCR-RET and FGFR1OP-RET cellular locations were investigated by confocal analysis in BaF/3-transduced cells. Both RET fusion gene products are located in the cytoplasm (Supplementary Figure 3) as BCR-ABL1. 17 Canonical pathways involved in transformation were analyzed by western blot analyses. BCR-RET and FGFR1OP-RET enhanced ERK phosphorylation in contrast to BCR-ABL1 P210 . BCR-RET is specifically associated with the phosphorylations of STAT3 and AKT after withdrawal of IL3. The STAT5 and b-catenin pathways were not modified by any of the RET fusion proteins (Supplementary Figure 4) .
RET fusion genes skew differentiation to the monocytic/ macrophage lineage To assess the impact of the two RET fusion genes regarding the hematopoietic differentiation, we infected primitive Figure 1 . Clinical response of BCR-RET to Imatinib and Sorafenib. White blood cell count in G/L evolution of case 2 from the initial diagnosis according to treatment: Imatinib at 400 mg/day (I) then Sorafenib at 800 mg/day (S8). The dose of Sorafenib was reduced due to toxicity to 400 mg/day (S4) and 200 mg/day (S2). Number of mitoses, normal or containing the t(10;22) translocation, are indicated at each time point where the karyotype was performed. 
lineage-negative hematopoietic cells with MIE-BCR-RET, MIE-FGFR1OP-RET, MIE-BCR-ABL1
P210 or MIE retroviruses. RET fusions skewed hematopoietic differentiation increasing the percentage of monocyte/macrophage colonies (CFU-M) in methylcellulose cultures (Figure 3a ). Cells were then recovered from the methylcellulose. Morphology and butyrate esterase staining revealed that the percentage of monocytes/macrophages cells is also higher in RET fusion gene-infected cells compared with the MIE or MIE-BCR-ABL1 P210 retroviruses (Figure 3b and Supplementary Figure 5) .
Murine bone marrow cells have a limited ability to grow after several replatings in methylcellulose cultures in presence of cytokines. 13 In a similar way to BCR-ABL1, 18 the two RET fusion genes do not confer to the infected cells the ability of forming colonies after the third replating (Figure 3c ).
DISCUSSION
We report here the first involvement of the RET TK in hematological malignancies, rearranged by translocation with two different fusion partners, BCR or FGFR1OP. These events have similar molecular consequences, the fusion of the RET TK domain with dimerization domains. RET is located in the 10q11 chromosomal band. One CMML case with a t(6;10)(q27;q11), a translocation identical to the case 1, has been reported in a 41-year-old man suffering from an atypical CMML syndrome associated with myelofibrosis. The disease rapidly evolved to acute monoblastic leukemia (M5a). 19 In addition, the 10q11 chromosomal band has been implicated in additional cases of monocytic AML, 20, 21 suggesting that RET TK activation is a rare but recurrent event in myelomonocytic leukemias, in a similar way to the activation of RET in 1-2% of lung and colorectal cancers. 6, 7 We also investigated the TK domain sequence of RET in 6 AML and 7 CMML patients expressing RET at the highest levels without detecting any point mutation in this region. A similar result was found in AML where the structure of RET was investigated by Southern blot and denaturing gradient gel electrophoresis in 17 patients. 22 The two RET fusion genes described here merge exon 12 of RET in 3 0 with BCR exon 4 or FGFR1OP exon 12 in 5 0 . The 5 0 part of the fusion genes encodes dimerization domains, in a similar way to all the fusion gene partners reported in papillary thyroid, lung and colorectal carcinomas associated with RET rearrangements (PTC1
, PCM1, ELKS and KIF5B 5-7 ). All RET fusion genes identified so far therefore contain the entire TK domain of RET and lose its signal sequence, extracellular ligand-binding and intracellular juxta-membrane domains. The latter domain has a negative effect on the RET signaling. 23 Both BCR and FGFR1OP domains kept in the fusion proteins have dimerization properties. 14, 24 Consequently, the oncogenic activity of RET fusion proteins could be a combination of a constitutive dimerization, higher expression and loss of negative regulatory elements. To assess the oncogenicity of FGFR1OP-RET and BCR-RET fusion gene products, we performed a BaF/3 transformation assay. In a similar way to BCR-ABL1, both RET fusion gene products conferred independence to IL3 to BaF/3 cells. Furthermore, RET fusion proteins skewed the differentiation of lineage-negative hematopoietic progenitors to the monocytic lineage. Nonetheless, these infected cells were unable to serially replate as BCR-ABL1. 18 These results suggested that the RET fusions are able to transform progenitors already engaged in the myelomonocytic differentiation.
RET is physiologically expressed by normal granulocytes, monocytes and macrophages. 25 RET is also expressed in AML and CMML as shown by Gattei et al. 25 and confirmed in our study, the expression being higher in monocytic and myelomonocytic AML and the most mature stages. In contrast, its expression is absent or weak in the other hematopoietic cell lineages (CD34 þ progenitors, eosinophils, B and T cells). 25 RET fusion proteins activated the phosphorylation of ERK, STAT3 and AKT proteins. The normal RET protein has been found to activate also ERK and AKT through a phosphorylation of its tyrosine residue 1062 and a subsequent activation of RAS pathway. [26] [27] [28] Phosphorylation of the tyrosine 705 of STAT3 and therefore its activation has also been associated with RET fusion genes found in thyroid carcinomas and was shown to be independent from JAK TKs. 29 Case 1 was allografted rapidly after its diagnosis. Case 2 was treated initially using Imatinib but the white blood cells count continued to increase suggesting an inefficacity of this TK inhibitor. After identification of the TK involved in the t(10;22)(q11;q11) rearrangement, the patient's treatment was switched to Sorafenib (Nexavar). Sorafenib was associated with complete hematological and clinical responses without karyotypic or molecular responses. A strong effect of Sorafenib against the fusion gene PTC3-RET was demonstrated with an IC50 of 47 nM. 15 A clinical effect of Sorafenib was also demonstrated in a phase II trial in patients with advanced medullary thyroid carcinomas where patients received Sorafenib 400 mg orally twice daily. Of 16 patients with sporadic RET mutations, 1 achieved partial response and 14 had stable disease. 30 In conclusion, CMML is a hematopoietic malignancy associated with the frequent activation of the RAS pathway, being mutated in 30% of CMML cases. 31 The RET fusion genes identified here seem to constitutively mimic the same signaling pathway than RAS mutations. 32, 33 In addition, the impact of the RET fusion genes on the monocytic lineage questions the role of the normal RET TK activity during the physiological monocytic differentiation. Finally, Sorafenib has a direct effect over the RET fusion protein occurring in CMML.
